☰

Susan M. Catalano, Ph.D. - Publications

Affiliations: 
Cognition Therapeutics Inc. 
Area:
Alzheimer's therapeutics
Website:
http://www.cogrx.com
Tree Info Grants Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Colom-Cadena M, Toombs J, Simzer E, Holt K, McGeachan R, Tulloch J, Jackson RJ, Catterson JH, Spires-Jones MP, Rose J, Waybright L, Caggiano AO, King D, Gobbo F, Davies C, ... ... Catalano SM, et al. Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer's disease. Acta Neuropathologica. 147: 32. PMID 38319380 DOI: 10.1007/s00401-023-02679-6  0.491
2024 van Dyck CH, Mecca AP, O'Dell RS, Bartlett HH, Diepenbrock NG, Huang Y, Hamby ME, Grundman M, Catalano SM, Caggiano AO, Carson RE. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease. Alzheimer's Research & Therapy. 16: 20. PMID 38273408 DOI: 10.1186/s13195-024-01382-2  0.487
2023 Lizama BN, Kahle J, Catalano SM, Caggiano AO, Grundman M, Hamby ME. Sigma-2 Receptors-From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases. International Journal of Molecular Sciences. 24. PMID 37047224 DOI: 10.3390/ijms24076251  0.347
2021 Rishton GM, Look GC, Ni ZJ, Zhang J, Wang Y, Huang Y, Wu X, Izzo NJ, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Catalano SM. Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease. Acs Medicinal Chemistry Letters. 12: 1389-1395. PMID 34531947 DOI: 10.1021/acsmedchemlett.1c00048  0.812
2021 LaBarbera KM, Limegrover C, Rehak C, Yurko R, Izzo NJ, Knezovich N, Watto E, Waybright L, Catalano SM. Modeling the mature CNS: A predictive screening platform for neurodegenerative disease drug discovery. Journal of Neuroscience Methods. 358: 109180. PMID 33836174 DOI: 10.1016/j.jneumeth.2021.109180  0.743
2021 Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Waybright L, Look G, Rishton G, Safferstein H, Hamby ME, Williams C, Sadlek K, Edwards HM, Davis CS, ... ... Catalano SM, et al. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 33559354 DOI: 10.1002/alz.12302  0.793
2021 Limegrover CS, Yurko R, Izzo NJ, LaBarbera KM, Rehak C, Look G, Rishton G, Safferstein H, Catalano SM. Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein. Journal of Neuroscience Research. PMID 33480104 DOI: 10.1002/jnr.24782  0.753
2020 Izzo NJ, Colom-Cadena M, Riad AA, Xu J, Singh M, Abate C, Cahill MA, Spires-Jones TL, Bowen WD, Mach RH, Catalano SM. Proceedings from the Fourth International Symposium on sigma-2 Receptors: Role in Health and Disease. Eneuro. PMID 33028631 DOI: 10.1523/ENEURO.0317-20.2020  0.311
2020 Limegrover CS, LeVine H, Izzo NJ, Yurko R, Mozzoni K, Rehak C, Sadlek K, Safferstein H, Catalano SM. Alzheimer's Protection Effect of A673T Mutation May Be Driven by Lower Aβ Oligomer Binding Affinity. Journal of Neurochemistry. PMID 33025581 DOI: 10.1111/jnc.15212  0.722
2020 Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. Alzheimer's Research & Therapy. 12: 21. PMID 32122400 DOI: 10.1186/S13195-020-00588-4  0.373
2019 Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, Guttendorf R, Higgin M, Pribyl J, Mozzoni K, Safferstein H, Catalano SM. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 5: 20-26. PMID 30723776 DOI: 10.1016/J.Trci.2018.11.001  0.799
2014 Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G, Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, ... ... Catalano SM, et al. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. Plos One. 9: e111899. PMID 25390692 DOI: 10.1371/Journal.Pone.0111899  0.742
2014 Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, ... ... Catalano SM, et al. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. Plos One. 9: e111898. PMID 25390368 DOI: 10.1371/Journal.Pone.0111898  0.744
2007 Look GC, Jerecic J, Cherbavaz DB, Pray TR, Breach JC, Crosier WJ, Igoudin L, Hironaka CM, Lowe RM, McEntee M, Ruslim-Litrus L, Wu HM, Zhang S, Catalano SM, Goure WF, et al. Discovery of ADDL--targeting small molecule drugs for Alzheimer's disease. Current Alzheimer Research. 4: 562-7. PMID 18220523 DOI: 10.2174/156720507783018271  0.473
2006 Catalano SM, Dodson EC, Henze DA, Joyce JG, Krafft GA, Kinney GG. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. Current Topics in Medicinal Chemistry. 6: 597-608. PMID 16712494 DOI: 10.2174/156802606776743066  0.457
2003 Hitoshi Y, Gururaja T, Pearsall DM, Lang W, Sharma P, Huang B, Catalano SM, McLaughlin J, Pali E, Peelle B, Vialard J, Janicot M, Wouters W, Luyten W, Bennett MK, et al. Cellular localization and antiproliferative effect of peptides discovered from a functional screen of a retrovirally delivered random peptide library. Chemistry & Biology. 10: 975-87. PMID 14583264 DOI: 10.1016/J.Chembiol.2003.09.009  0.431
2000 Braisted JE, Catalano SM, Stimac R, Kennedy TE, Tessier-Lavigne M, Shatz CJ, O'Leary DD. Netrin-1 promotes thalamic axon growth and is required for proper development of the thalamocortical projection. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 5792-801. PMID 10908620 DOI: 10.1523/Jneurosci.20-15-05792.2000  0.544
1998 Catalano SM, Shatz CJ. Activity-dependent cortical target selection by thalamic axons. Science (New York, N.Y.). 281: 559-62. PMID 9677198 DOI: 10.1126/Science.281.5376.559  0.549
1998 Catalano SM, Messersmith EK, Goodman CS, Shatz CJ, Chédotal A. Many major CNS axon projections develop normally in the absence of semaphorin III. Molecular and Cellular Neurosciences. 11: 173-82. PMID 9675049 DOI: 10.1006/Mcne.1998.0687  0.561
1997 Catalano SM, Chang CK, Shatz CJ. Activity-dependent regulation of NMDAR1 immunoreactivity in the developing visual cortex. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 17: 8376-90. PMID 9334411 DOI: 10.1523/Jneurosci.17-21-08376.1997  0.563
Show low-probability matches.